TLR9 and cancer: However, it is worth mentioning that TLR7 and TLR9 expression levels were negatively linked with cancer cell sensitivity to Irofulven, an alkylating agent, indicating that as TLR7 and TLR9 expression levels grew, the risk of Irofulven resistance increased.